Figure 1.
Patient Disposition – Consort Diagram.
Table 1.
Baseline Characteristics.
Figure 2.
Mean Absolute Reduction in LDL-C (value closest to 2 weeks after the end of study treatment).
Table 2.
Baseline Lipid Concentrations and Effect of Treatment on Lipid Parameters.
Figure 3.
Mean Percent Change from Baseline to Week 28.
Error bars indicate 95% CI. Placebo (n = 18); mipomersen 200 mg weekly (n = 39). (A) Low-density lipoprotein cholesterol (LDL-C) (B) Apolipoprotein B (Apo B) (C) Lipoprotein(a) (Lp(a)) (D) Non-high density lipoprotein cholesterol (non-HDL-C) (E) Total Cholesterol.
Table 3.
On-Treatment Adverse Events Reported in at Least 10% of Mipomersen Patients.
Table 4.
Laboratory Abnormalities of Interest.
Table 5.
Liver Fat Content, Fasting Levels of Alanine Aminotransferase, and Percent Change in LDL-C in Patients with Post-Baseline For-Cause Magnetic Resonance Imaging Assessments.